Outcomes and impact of device iterations in mitral valve transcatheter edge-to-edge repair: the REPAIR study
Background - The PASCAL P10 system for mitral valve transcatheter edge-to-edge repair has undergone iterations, including introduction of the narrower Ace implant and the Precision delivery system. - Objectives - This study sought to evaluate outcomes and the impact of PASCAL mitral valve transcathe...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
10 March 2025
|
| In: |
JACC Cardiovascular interventions
Year: 2025, Volume: 18, Issue: 5, Pages: 573-586 |
| ISSN: | 1876-7605 |
| DOI: | 10.1016/j.jcin.2024.11.016 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jcin.2024.11.016 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1936879824017126 
|
| Author Notes: | Philipp von Stein, MD, Lukas Stolz, MD, Jean Marc Haurand, MD, Matthias Gröger, MD, Felix Rudolph, MD, Donika Mustafa, Jannik Jobst, MD, Christoph Alexander Mues, MD, Amir Abbas Mahabadi, MD, Isabel A. Hörbrand, MD, Carl Schulz, MD, Atsushi Sugiura, MD, Tobias Ruf, MD, Philipp Lurz, MD, Muhammed Gerçek, MD, Patrick Horn, MD, Mirjam Kessler, MD, Tienush Rassaf, MD, Marcel Weber, MD, Tobias Kister, MD, Niklas Schofer, MD, Mathias Konstandin, MD, Florian Schindhelm, MD, Helge Möllmann, MD, Bernhard Unsöld, MD, Stephan Baldus, MD, Wolfgang Rottbauer, MD, Volker Rudolph, MD, Jörg Hausleiter, MD, Roman Pfister, MD, Victor Mauri, MD, the REPAIR Investigators |
| Summary: | Background - The PASCAL P10 system for mitral valve transcatheter edge-to-edge repair has undergone iterations, including introduction of the narrower Ace implant and the Precision delivery system. - Objectives - This study sought to evaluate outcomes and the impact of PASCAL mitral valve transcatheter edge-to-edge repair device iterations. - Methods - The REPAIR (REgistry of PAscal for mltral Regurgitation) study is an investigator-initiated, multicenter registry including consecutive patients with mitral regurgitation (MR) treated from 2019 to 2024. Patients were stratified by device iteration: P10only, P10/AceGen1 (introduction of Ace), and P10/AcePrec (introduction of Precision). The primary endpoint was MR ≤1+ at discharge; secondary endpoints included technical success and MR durability (discharge vs 30 days, 1 year, and 2 years). - Results - A total of 2,165 patients (mean age 78 ± 10 years, 44% female, 85% in NYHA functional class ≥III, EuroSCORE II [European System for Cardiac Operative Risk Evaluation II] 4.9% [Q1-Q3: 3.0% to 8.1%]) were included: 660 P10only, 945 P10/AceGen1, and 560 P10/AcePrec. Median follow-up was 510 days (Q1-Q3: 369-874 days). Primary (47% [n = 1,019 of 2,142]) and secondary (52% [n = 1,123 of 2,142]) MR etiology did not change across device iterations (P = 0.547). Technical success was achieved in 97.0% (n = 2,099 of 2,165) with similar rates across device iterations (P = 0.290). MR ≤1+ was achieved in 72% (n = 1,397 of 2,085), improving with device iterations (P10only: 66% [n = 422 of 638], P10/AceGen1: 73% [n = 661 of 906], P10/AcePrec: 77% [n = 414 of 541]; P < 0.001). MR grades of ≤1+ and ≤2+ slightly worsened at 30 days, 1 year, and 2 years, primarily in patients with primary MR, with no differences across iterations. - Conclusions - Device iterations of the PASCAL system resulted in increasing rates of achieving MR reduction to ≤1+ at discharge, with stable and high technical success rates. A slight deterioration of the initial result warrants further investigation. |
|---|---|
| Item Description: | Online verfügbar: 25. November 2024, Artikelversion: 10. März 2025 Gesehen am 09.09.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1876-7605 |
| DOI: | 10.1016/j.jcin.2024.11.016 |